Compare Recursion Pharmaceuticals Inc (RXRX) vs Wayfair Inc (W) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Wayfair Inc — how do they compare? Recursion Pharmaceuticals Inc trades at $3.35 (market cap $1.78B), while Wayfair Inc trades at $103.55 (market cap $14.14B). The key difference: Wayfair Inc is far larger — about 7.9× Recursion Pharmaceuticals Inc's market cap, and Wayfair Inc is trading nearer its 52-week high, Recursion Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| RXRX | W | |
|---|---|---|
Market Cap | $1.78B | $14.14B |
Sector | Health | Consumer Cyclical |
52-Week High | $6.79 | $119.05 |
52-Week Low | $2.84 | $57.40 |
Enterprise Value | $1.30B | $16.48B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.22, up 1.26% today, with a neutral technical signal and bearish moving averages. The company reported a Q2 2026 EPS miss of -$0.25 versus -$0.24 expected, with revenue declining year-over-year. Financials show steep losses, including a net income margin of -961.97% in 2026, though cash flow from financing activities provides a runway through early 2028. Recent news highlights partnership progress with Genentech but notes competitive pressures and slow revenue growth.
Outlook remains speculative due to high cash burn and unproven commercial scalability, posing significant risk. Analyst consensus is mixed with 40% buy ratings, reflecting optimism for AI-driven drug discovery potential against persistent profitability challenges. Investment appeal hinges on pipeline milestones, but current fundamentals warrant caution.
Wayfair (W) trades at $106.59, up 2.44% today, showing strong momentum following better-than-expected Q2 2026 earnings. Technical indicators signal a bullish trend with the stock approaching key resistance levels. Fundamentally, the company delivered 7.5% year-over-year revenue growth in Q2 2026, though it continues to operate at a net loss margin of -2.49%. Recent news highlights strong U.S. segment performance and market share gains despite international challenges.
The outlook remains cautiously optimistic with analysts projecting 51.78% buy ratings and a $122 consensus price target, representing 14.4% upside potential. Key risks include persistent unprofitability, high debt-to-asset ratio of 95.11%, and uneven consumer demand. The stock's premium valuation at 151.17x EV/EBITDA requires continued execution on growth and margin expansion targets to justify current levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Wayfair Inc
Wayfair is a global leader in home goods, operating a massive digital marketplace that connects millions of consumers with thousands of suppliers. It utilizes an asset-light, inventory-light model combined with a proprietary logistics network (CastleGate) and an accelerating brick-and-mortar presence to deliver an end-to-end shopping experience for everything from decor to full home renovations.
Read more on W →
